Dimension Therapeutics Appoints Successful Biopharma Leader Mary Thistle as Chief Business Officer

- Dimension Is Advancing Toward Clinical Testing a Growing Portfolio of Gene Therapy Treatments for Serious, Genetic Disorders of the Liver -

CAMBRIDGE, Mass.--()--Dimension Therapeutics, Inc. (“Dimension” or the “Company”), a rare disease company advancing novel treatments for diverse genetic disorders of the liver based upon an AAV gene therapy platform, today announced that Mary Thistle, former senior vice president, business development at Cubist Pharmaceuticals, has been appointed to the newly created position of chief business officer. Ms. Thistle will report directly to Dimension’s CEO Annalisa Jenkins, MBBS, MRCP, and her appointment is effective February 2.

“We are thrilled that Mary is joining the leadership team at Dimension,” said Dr. Jenkins. “She is a highly regarded biopharma executive with a strong track record in driving sustainable growth and building portfolios of important new therapies through corporate development and strategic transactions. Mary will be a key part of our team working to realize the potential of Dimension’s innovative and growing pipeline, which is expected to enter clinical testing this year, offering the potential of meaningful medical progress to patients living with severe diseases.”

Ms. Thistle brings extensive experience in the life sciences industry, serving in senior finance, operations, and business development roles. At Cubist, she was responsible for four major acquisitions, including Trius Therapeutics and Optimer Pharmaceuticals, significantly driving growth of the company’s pipeline prior to Cubist’s recent $9.5 billion acquisition by Merck. Prior to this, Ms. Thistle held leadership positions at ViaCell, Inc., including senior vice president, business development, and senior vice president and general manager, ViaCell Reproductive Health. In the latter role, she was responsible for the expansion of the company’s ViaCord™ umbilical blood-banking business, positioning ViaCell for eventual acquisition by PerkinElmer. She also helped set the stage for ViaCell’s successful IPO in her previous role as vice president, finance and corporate planning. Ms. Thistle began her career in finance as a certified public accountant working with both private and public companies. She received her B.A. degree in accounting from the University of Massachusetts.

Ms. Thistle stated, “It’s a very exciting time to join Dimension. As gene therapy technologies have matured, they have shown strong promise in treating diseases for which there are currently few or no treatment options. Dimension’s novel gene therapy platform has enabled a broad pipeline of product candidates, and the Company has assembled a world-class leadership team. I look forward to contributing to the potential we have at hand to realize this new wave of innovation and the offer of new hope for these patients and their families.”

About Dimension Therapeutics

Dimension Therapeutics, Inc. is a gene therapy company developing novel treatments for patients with liver-associated rare diseases, including hemophilia. Dimension is strategically building a broad product development pipeline based on an industry-leading, extensively validated adeno-associated virus (AAV) platform and is advancing multiple gene therapy programs toward clinical development. These programs include a collaboration with Bayer HealthCare in hemophilia A and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple best-in-class AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases. In June 2014 the company announced a Series A financing with participation by leading investors Fidelity Biosciences and OrbiMed. For more information, please visit www.dimensiontx.com.

Contacts

Justin Jackson, Burns McClellan, on behalf of Dimension Therapeutics
212-213-0006, ext.327
jjackson@burnsmc.com

Contacts

Justin Jackson, Burns McClellan, on behalf of Dimension Therapeutics
212-213-0006, ext.327
jjackson@burnsmc.com